EUR 1.0
(-0.38%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 9.86 Million EUR | -19.82% |
2022 | 14.03 Million EUR | 37.25% |
2021 | 10.22 Million EUR | 36.3% |
2020 | 7.5 Million EUR | 22.06% |
2019 | 6.14 Million EUR | 23.88% |
2018 | 4.96 Million EUR | 109.41% |
2017 | 2.37 Million EUR | 94.58% |
2016 | 1.21 Million EUR | 31.39% |
2015 | 927 Thousand EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.78 Million EUR | 0.0% |
2023 Q4 | 3.79 Million EUR | 0.0% |
2023 FY | 11.25 Million EUR | -19.82% |
2023 Q2 | 6.04 Million EUR | 0.0% |
2022 Q4 | 7.91 Million EUR | 0.0% |
2022 FY | 14.03 Million EUR | 37.25% |
2022 Q2 | 6.12 Million EUR | 0.0% |
2021 FY | 10.22 Million EUR | 36.3% |
2021 Q2 | 3.68 Million EUR | 0.0% |
2021 Q4 | 6.54 Million EUR | 0.0% |
2020 Q4 | 4.7 Million EUR | 0.0% |
2020 FY | 7.5 Million EUR | 22.06% |
2020 Q2 | 2.8 Million EUR | 0.0% |
2019 FY | 6.14 Million EUR | 23.88% |
2019 Q4 | 2.93 Million EUR | 0.0% |
2019 Q2 | 3.21 Million EUR | 0.0% |
2018 FY | 4.96 Million EUR | 109.41% |
2018 Q4 | 3.06 Million EUR | 0.0% |
2018 Q2 | 1.9 Million EUR | 0.0% |
2017 Q4 | 1.99 Million EUR | 0.0% |
2017 FY | 2.37 Million EUR | 94.58% |
2017 Q2 | 374 Thousand EUR | 0.0% |
2016 Q1 | 64.25 Thousand EUR | 0.0% |
2016 FY | 1.21 Million EUR | 31.39% |
2016 Q4 | 390 Thousand EUR | 0.0% |
2016 Q2 | 180 Thousand EUR | 180.16% |
2015 Q4 | 64.25 Thousand EUR | 0.0% |
2015 FY | 927 Thousand EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ABIONYX Pharma SA | 4.17 Million EUR | -136.27% |
ABIVAX Société Anonyme | 127.37 Million EUR | 92.252% |
Adocia SA | 15.62 Million EUR | 36.855% |
Aelis Farma SA | 18.81 Million EUR | 47.558% |
Biophytis S.A. | 14.33 Million EUR | 31.145% |
Advicenne S.A. | 8.21 Million EUR | -20.134% |
genOway Société anonyme | 16.73 Million EUR | 41.039% |
IntegraGen SA | 5.35 Million EUR | -84.381% |
Medesis Pharma S.A. | 1.56 Million EUR | -530.78% |
Neovacs S.A. | 10.34 Million EUR | 4.588% |
NFL Biosciences SA | 4.37 Million EUR | -125.611% |
Plant Advanced Technologies SA | 2.76 Million EUR | -256.945% |
Quantum Genomics Société Anonyme | 1.71 Million EUR | -474.459% |
Sensorion SA | 27.05 Million EUR | 63.521% |
Theranexus Société Anonyme | 3 Million EUR | -228.421% |
TME Pharma N.V. | 5.49 Million EUR | -79.534% |
TheraVet SA | 1.64 Million EUR | -500.19% |
Valerio Therapeutics Société anonyme | 20.32 Million EUR | 51.432% |
DBV Technologies S.A. | 89.4 Million EUR | 88.962% |
Genfit S.A. | 54.8 Million EUR | 81.992% |
GeNeuro SA | 14.35 Million EUR | 31.261% |
Innate Pharma S.A. | 64.57 Million EUR | 84.716% |
Inventiva S.A. | 120.18 Million EUR | 91.789% |
MaaT Pharma SA | 21.59 Million EUR | 54.306% |
MedinCell S.A. | 32.92 Million EUR | 70.023% |
Nanobiotix S.A. | 58.92 Million EUR | 83.252% |
OSE Immunotherapeutics SA | 23.58 Million EUR | 58.163% |
Poxel S.A. | 28.76 Million EUR | 65.691% |
GenSight Biologics S.A. | 32.66 Million EUR | 69.783% |
Transgene SA | 31.23 Million EUR | 68.4% |
Valneva SE | 134.92 Million EUR | 92.686% |